VRCI Verici Dx plc

0.0024USD0.1850 GBp · LSE0.00%Mkt Cap: 16.23M USDP/E: —

Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transp…

Institutional holders2 on file

Key Statistics

Company
Market Cap16.23M USD
Enterprise Value1.62M USD
Revenue (TTM)3.52M USD
Gross Profit2.84M USD
Net Income (TTM)-6.93M USD
Revenue/Share0.0020 USD
Last Price0.0024 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees23
CountryGB
SectorHealthcare
IndustryDiagnostics & Research
ISINGB00BM8HZD43
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.17
EV/Revenue0.46
P/S3.50
P/B0.62
EPS (TTM)0.00 USD
EPS (Forward)0.00 USD
52W Range
0.00231% of range0.0129
52W High0.0129 USD
52W Low0.0023 USD
Profitability
Gross Margin77.46%
Oper. Margin-223.74%
EBITDA Margin-207.69%
Profit Margin-189.22%
ROE-106.58%
ROA-87.32%
ROIC-207.56%
ROCE-105.75%
Growth
Revenue Growth-7.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.27M USD
CapEx (TTM)189.00K USD
FCF Margin-166.39%
FCF Yield-36.11%
Net Debt-1.63M USD
Net Debt/EBITDA0.22
Net Debt/FCF—
Balance Sheet
Debt/Equity0.03
Current Ratio2.81
Quick Ratio2.53
Book Value/Sh0.0030 USD
Cash/Share0.0020 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.0382 USD
Upside (mean)+1467.6%
Target Range0.0382 USD – 0.0382 USD
# Analysts1
Ownership
Shares Out.6.66B
Float959.60M
Insiders2.36%
Institutions49.46%
Technical
SMA 500.0028 (-13.9%)
SMA 2000.0049 (-49.9%)
Beta1.17
S&P 52W Chg12.00%
Avg Vol (30d)17.71M
Avg Vol (10d)5.75M
Technical Indicators
RSI (14)22.8
MACD-0.0091
MACD Signal-0.0068
MACD Hist.-0.0023
BB Upper0.0031 USD
BB Middle0.0027 USD
BB Lower0.0024 USD
BB Width24.05%
ATR (14)0.0002 USD
Vol Ratio (20d)0.13x

About Verici Dx (LON: VRCI)

›

Verici Dx (LON: VRCI) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 23 employees.

The shares were at 0.1850 GBp on 19 November 2026, down 74.5% over 52 weeks. Its 52-week range is 0.1735 GBp to 0.9790 GBp: the price is 81.1% below the high and 6.6% above the low.

Its market capitalisation is 12.33M GBP.

Verici Dx reports return on equity of -106.6%, an operating margin of -223.7% and revenue down 7.4% year over year.

It holds more cash than debt, a net cash position of 1.63M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.